Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)-Reference-Cited by-同舟云学术

Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)

Published:2016-04 Issue:4 Volume:16 Page:421-430
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Barrera Carlos M,Mykietiuk Analia,Metev Hristo,Nitu Mimi Floarea,Karimjee Najumuddin,Doreski Pablo Alexis,Mitha Ismail,Tanaseanu Cristina Mihaela,Molina Joseph McDermott,Antonovsky Yuri,Van Rensburg Dirkie Johanna,Rowe Brian H,Flores-Figueroa Jose,Rewerska Barbara,Clark Kay,Keedy Kara,Sheets Amanda,Scott Drusilla,Horwith Gary,Das Anita F,Jamieson Brian,Fernandes Prabhavathi,Oldach David

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference42 articles.

1. Clinical and economic burden of community-acquired pneumonia among adults in Europe;Welte;Thorax,2012

2. FOCUS 1: a randomized, double-blinded, multicentre phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia;File;J Antimicrob Chemother,2011

3. Focus 2: a randomized, double-blinded, multicenter, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia;Low;J Antimicrob Chemother,2011

4. Community-acquired pneumonia;Musher;N Engl J Med,2014

5. Community acquired pneumonia requiring hospitalization among US adults;Jain;N Engl J Med,2015

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibiotic Strategies for Severe Community-Acquired Pneumonia;Seminars in Respiratory and Critical Care Medicine;2024-02-01

2. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial;The Lancet Respiratory Medicine;2024-01

3. Macrolides and Immunomodulation: Today and the Future;Macrolides as Immunomodulatory Agents;2024

4. Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial aetiology;International Journal of Antimicrobial Agents;2023-10

5. Solithromycin inhibits IL-13-induced goblet cell hyperplasia and MUC5AC, CLCA1, and ANO1 in human bronchial epithelial cells;PeerJ;2023-01-17